Literature DB >> 8137472

The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma.

S C Chen1, S L Lian, W Y Chang.   

Abstract

To investigate the effect of external radiotherapy in the control of portal vein invasion (PVI) in hepatocellular carcinoma (HCC), ten patients with cytologically confirmed unresectable HCC were recruited for study. All of the patients were assigned Pugh's classification A, and all had only unilateral PV involvement. The main tumors were treated by transcatheter arterial embolization. The PVI was irradiated with a dose of 3000-5000 cGY using a linear accelerator under localization by real-time ultrasound. All ten patients responded to the external irradiation, with complete disappearance of the PVI occurring in five and partial shrinkage, in the other five. However, the HCC extended to the contralateral PV in two patients, although the irradiated lesion had shrunk. Both patients had shown involvement of the main PV in the initial study. Six patients died after 3, 6, 7, 7, 8, and 10 months, respectively, due to advance of the HCC, rupture, liver failure, and respiratory failure. The others survived for longer than 6 months and remain under follow-up. The branch of PVI at discovery might have an important bearing on the effect of the radiotherapy. No postirradiation hepatitis or other complication was observed.

Entities:  

Mesh:

Year:  1994        PMID: 8137472     DOI: 10.1007/bf00686683

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  PRIMARY LIVER CARCINOMA. AUTOPSY STUDY OF 60 CASES.

Authors:  R B PATTON; R C HORN
Journal:  Cancer       Date:  1964-06       Impact factor: 6.860

2.  Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma.

Authors:  A M Cochrane; I M Murray-Lyon; D M Brinkley; R Williams
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  [Study of 45 patients with hepatocellular carcinoma complicating occlusion of the main portal vein].

Authors:  T Kanno; K Kim; N Kurioka; S Harihara; S Yamamoto; T Monna; H Nakatsuka; K Minakuchi
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1985-05

4.  Human radiation hepatitis. A morphologic study with emphasis on the late changes.

Authors:  K Lewin; R R Millis
Journal:  Arch Pathol       Date:  1973-07

5.  Sonographic evaluation of portal vein thrombosis in hepatocellular carcinoma and liver metastasis.

Authors:  S C Chen; M Y Hsieh; Z Y Lin; L Y Wang; C M Jan; C Y Chen; H W Liu; W Y Chang; L T Chen; W L Chuang
Journal:  Gaoxiong Yi Xue Ke Xue Za Zhi       Date:  1986-06

6.  Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi.

Authors:  K Kumada; K Ozawa; R Okamoto; T Takayasu; M Yamaguchi; Y Yamamoto; H Higashiyama; S Morikawa; H Sasaki; Y Shimahara
Journal:  Surgery       Date:  1990-11       Impact factor: 3.982

7.  Radiotherapy in the treatment of hepatocellular carcinoma and its metastases.

Authors:  S C Chen; S L Lian; W L Chuang; M Y Hsieh; L Y Wang; W Y Chang; Y H Ho
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  7 in total
  14 in total

1.  Post-radiation survival time in hepatocellular carcinoma based on predictors for CT-determined, transarterial embolization and various other parameters.

Authors:  Ting-Kai Leung; Chi-Ming Lee; Li-Kuo Shen; Hsi-Chi Chen; Yu-Cheng Kuo; Jeng-Fong Chiou
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 2.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

3.  Radiation therapy for portal venous invasion by hepatocellular carcinoma.

Authors:  Keiichi Nakagawa; Hideomi Yamashita; Kenshiro Shiraishi; Naoki Nakamura; Masao Tago; Hiroshi Igaki; Yoshio Hosoi; Shuichiro Shiina; Masao Omata; Masatoshi Makuuchi; Kuni Ohtomo
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

4.  Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.

Authors:  J Fan; Z Q Wu; Z Y Tang; J Zhou; S J Qiu; Z C Ma; X D Zhou; S L Ye
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

5.  Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy.

Authors:  Mi Yean Yang; Soung Won Jeong; Dong Kyun Kim; Sang Gyune Kim; Jae Young Jang; Young Seok Kim; Joon Seong Lee; Boo Sung Kim; Jung Hoon Kim; Yong Jae Kim
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

Review 6.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Authors:  Christopher H Crane; Eugene J Koay
Journal:  Cancer       Date:  2016-03-07       Impact factor: 6.860

7.  Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment.

Authors:  Xiao-Jun Qian; Ren-You Zhai; Ding-Ke Dai; Ping Yu; Li Gao
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 8.  Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

9.  Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.

Authors:  Soung Won Jeong; Jae Young Jang; Kwang Yeun Shim; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; Kyoung Ha Kim; Jung Hoon Kim
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

Review 10.  Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus.

Authors:  Satoshi Katagiri; Masakazu Yamamoto
Journal:  Surg Today       Date:  2013-04-17       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.